Retroviral gene transfer resulting in transgene expression selectively restricted to specific cell lineages would be desirable for many gene therapeutic applications. Such transcriptional targeting of retroviruses can be accomplished by employing eukaryotic control elements in self-inactivating (SIN) retroviral vectors, but use of these vectors is complicated by an accompanying reduction in viral titers. To overcome this restriction and address the influence of the post-transcriptional regulatory element of the Woodchuck hepatitis virus (WPRE) on viral titers and transgene expression, we developed SIN-vectors with and without WPRE. Using the enhancer-promoter of the Spleen Focus Forming virus (SFFV) to direct eGFP expression to multiple hematopoietic lineages, we show that WPRE significantly (410 Â ) increased viral titers (410 6 per ml of unconcentrated supernatant) and transgene expression in NIH3T3 cells in vitro. Gene expression in vivo was significantly lowered in lymphoid cells, but not in myeloid cells when WPRE was present. Furthermore, the use of WPRE in combination with the B-cell lineage-specific CD19 promoter significantly increased viral titers and allowed targeting of transgene expression by SIN-vectors specifically to B cells throughout their development in primary and secondary lymphoid organs.
Introduction
Retroviral vectors are an efficient gene delivery system for many gene therapeutic applications and, to date, the only tool to achieve efficient stable genomic integration of a transgene with a predictable copy number. [1] [2] [3] [4] Controlling expression of the transferred gene in a tissue-or cell-specific manner is an important goal in retroviral vector technology. Spatially, temporally or quantitatively inappropriate transgene expression can harbor unpredictable and potentially harmful effects, which are avoidable by the use of cell-specific regulatory elements. Transcriptional targeting by insertion of an independent and cell-specific transcriptional unit into the framework of retroviral vectors is problematic, as the viral enhancer-promoter located in the 5 0 long terminal repeat (LTR) interferes with activity and regulation of internal cis-acting elements. [5] [6] [7] [8] [9] The use of self-inactivating (SIN) retroviral vectors lacking viral promoterelements located in the U3 region and allowing transcription from an internal promoter has been proposed to overcome this problem. However, when using vectors based on murine leukemia viruses (MLV), these approaches have been hampered by very low viral titers of SIN-vectors. [10] [11] [12] [13] The life cycle of retroviruses requires export of unspliced and partially spliced RNA into the cytoplasm, but nuclear export of unspliced RNA usually fails. Mechanisms have evolved that circumvent the need for splicing, but these are associated with cis-acting elements and their corresponding viral or cellular factors mediating RNA transport. Human hepatitis B virus and Woodchuck hepatitis virus employ posttranscriptional elements (HPRE and WPRE, respectively) for the nuclear export of their intronless RNA. 14, 15 Transgene expression from retroviral or lentiviral vectors could be improved by including the WPRE element, although the effect was strongly influenced by the type of promoter being used. [16] [17] [18] [19] [20] WPRE stimulates nuclear RNA export and probably affects 3 0 -end processing and polyadenylation as well. 19, 21, 22 Thus, we speculated that WPRE might also have a beneficial effect on viral titers of SIN vectors, thereby compensating for their low viral titers.
The B-cell differentiation antigen CD19, a 95-kDA transmembrane glycoprotein that serves as B-cell-specific marker is expressed throughout B lymphocyte development from the pro-B through the mature B-cell stages, with the exception of terminally differentiated plasma cells. [23] [24] [25] CD19 participates in B lymphocyte development, B-cell activation, maturation of memory B cells and regulation of tolerance. 26, 27 As approximately 4.2 kb of the human CD19 promoter region were able to direct B-cell-specific expression of heterologous genes in transgenic mice, 26, 28 we used the CD19 promoter to develop a B-cell-specific SIN vector with an MLV backbone. In order to study the impact of WPRE on viral titers and transgene expression of SIN-vectors not only in B cells, but also in the context of different cell lineages of hematopoietic origin, we utilized the strong enhancer-promoter of the spleen focus forming virus (SFFV) to drive ubiquitous transgene expression. We demonstrate in a side-by-side comparison that WPRE enhances viral titers independent of the employed promoter, allowing efficient gene transfer of SIN-vectors into primary hematopoietic cells. Surprisingly, transgene expression was enhanced in vitro, but not in different hematopoietic lineages in vivo. Furthermore, we show that efficient gene transfer and transcriptional targeting to B cells can be accomplished using a SIN-vector employing a fragment of the human CD19 promoter in combination with WPRE.
Results

WPRE enhances viral titers of the SIN-vector and increases transgene expression in vitro
The WPRE is widely used to enhance transgene expression, particularly in the context of MLV-and lentiviral vectors. [16] [17] [18] [19] [20] To test whether WPRE enhances the performance of SIN-vectors, that is, increases viral titer and/or transgene expression, we first determined the viral titer of the SIN-vector ( Figure 1 ) with (SIN-SF-W) and without WPRE (SIN-SF). The SFFV enhancer-promoter, which is active throughout all developmental stages and lineages of the hematopoietic system, 29 was chosen as internal promoter. In order to study promoter activity in vitro and in vivo, eGFP was employed as marker permitting direct quantification and detection of the proportion of transduced cells as well as their transgene expression levels. Direct comparison of viral titer of the vector with and without WPRE showed that WPRE enhanced the titer up to 14-fold when titrated on NIH3T3 cells (Figure 2a , pSIN-SF-W: 3.5-18.9 Â 10 5 versus pSIN-SF: 0.6-2.8 Â 10
5 TU/ml, P ¼ 0.003, Student's t-test). However, to exclude the possibility that this observed rise in titer for the WPRE-containing vector is not related to increased integrated vector sequences, but to improved transgene expression from this vector, viral titer were determined by quantitative real-time PCR (Figure 2b ). We therefore measured viral titer based on integrated vector sequences in NIH 3T3 cells. The titer of the vector without WPRE was on average six-fold lower as compared to the vector employing WPRE A human CD19 promoter-driven SIN vector displays B-cell-specific transgene expression in vivo
In an attempt to develop a B-cell-specific SIN-vector, the SFFV enhancer-promoter was substituted with a 999-bp fragment (À1018 to À19 bp) of the promoter region of the human CD19 gene (Figure 1 ). This region contains binding sites for the transcription factors SP1/Egr-1, Bcell-specific activator protein (BSAP) and early B-cell factor (EBF), which have been suggested to regulate the promoter activity. 30, 31 The vector was created with and without WPRE (SIN-CD19-W and SIN-CD19, respectively) for two reasons. Our data obtained with the SINvector employing the SFFV enhancer-promoter indicated that WPRE would be crucial to obtain satisfying titer of the SIN vector in the context of the CD19 promoter. We also wanted to address the possibility that the observed negative influence of WPRE on transgene expression in lymphoid cells in vivo might be related to the nature of the internal promoter being used. In order to determine the viral titer of the CD19 promoter-driven vectors in combination with and without WPRE, quantitative real-time PCR of integrated retroviral sequences in NIH 3T3 cells was performed ( Figure 4a ). As expected from previous experiments with the SFFV-driven vectors (Figure 2 ), the titer of pSIN-CD19-W, employing WPRE, was on average two-fold higher as compared to pSIN-CD19, lacking the post-transcriptional regulatory element (10.7 Â 10 The B-cell-specific SIN-vector confers long-term transgene expression in vivo Retroviral transgene expression can be lost over time due to inactivation of the promoter. We therefore asked if long-term expression from our B-cell-specific promoter could be observed. Peripheral blood from SIN-CD19-W bone marrow chimeras was analyzed at early and late time-points after bone marrow reconstitution (Figure 5c ). At week 6 post-transplantation, an average of 26.072.8% B cells (n ¼ 8) expressed eGFP. Almost 1 year later, at week 46, only one out of eight animals (#4) displayed a notable reduction of eGFP-positive B cells, while the remaining were found to have either higher (#2, #3) or a 1.3-2.5-fold reduced frequency of transgene-expressing B cells in the range of 10.0-22.9%. However, on average no statistically significant difference was observed for the mice at week 6 and 46.
Discussion
In an attempt to develop a SIN-vector for efficient gene transfer and transcriptional targeting to B cells, we systematically analyzed the influence of WPRE on viral titer and gene expression in context of a ubiquitous or B-cell-specific promoter. WPRE enhanced viral titer of both vectors (Figure 2a and 4a) which, in line with the observed increase of transgene expression in fibroblasts suggests that WPRE might increase RNA levels driven from the internal promoter as well as retroviral fulllength RNA expressed from the 5 0 LTR promoter of the transfected plasmid. Thus, we could produce SINvectors at sufficient titer for use with primary hematopoietic cells, obviating the need to concentrate vector supernatants (Figures 3a and 4) . The highly structured WPRE may compensate the reported negative effect of LTR enhancer-promoter deletions on the architecture of the retroviral RNA. 11, 17, [32] [33] [34] The titer-enhancing effect of WPRE observed here in the context of SINvectors is significantly greater than that previously reported for LTR-driven MLV vectors. 19 Lentiviral vector titers are less sensitive to deletions in the U3 region of the LTR;
35-37 accordingly, WPRE was not found to have a similarly strong effect on lentiviral titers as observed here for MLV SIN-vectors. 22, 38 Surprisingly, in the context of the SIN-vector with the internal SFFV enhancer-promoter, WPRE increased transgene expression in NIH3T3 cells in vitro, but not in hematopoietic cells in vivo (Figures 2c and 3b) . Analysis of spleen and long-term examination of peripheral blood revealed significantly reduced transgene expression in T and B cells. In contrast, WPRE had no effect on eGFP expression of transduced myeloid cells. Therefore, WPRE effects depend heavily on the cellular context. These data are in agreement with other reports describing a negative effect of WPRE on transgene expression from lentiviral SIN-vectors depending on promoter 39 and target cell B-cell-specific SIN vector M Werner et al type. 18, 39 Further supporting the context-dependence of WPRE function, other studies showed a positive effect of WPRE on transgene expression from lenti-and retroviral LTR-driven or SIN-vectors. 17, 20, 40, 41 The closely related HPRE interacts with host nuclear factors, which might be directly or indirectly involved in nuclear transport of unspliced mRNA. 42 WPRE recently was demonstrated to exert its function in both a CRM-1-dependent and -independent manner, and different cell types, depending on their functional and developmental status, might regulate these pathways unequally. 43 Toxic effects of eGFP expression resulting in selection of low expressing clones are unlikely to account for the observed negative effect of WPRE; if so, we would expect equal eGFP expression in both vector groups but not consistently and significantly lower transgene expression in the group with the vector employing WPRE. Furthermore, mice transplanted with SIN-SF-W-transduced cells at high MOI displayed greater MFI values than those transplanted with cells transduced at low MOI (Figure 3a) . Finally, the frequency of transgenic B and T cells did not change over time (data not shown) further arguing against toxic effects of eGFP.
For the B-cell-specific vector with and without WPRE, no difference in transgene expression was observed (Figure 4b) . However, the two-fold higher viral titer leading to an increased frequency of transgenic B cells in vivo when the vector with WPRE was used results in a higher MOI. This suggests that the negative effect of WPRE on transgene expression in lymphoid cells is independent of the internal promoters used here, but we cannot exclude the possibility that WPRE exerts different effects in combination with different promoters. 18 In summary, use of WPRE in combination with SIN-vectors is recommended to overcome their limiting low titers and thereby strongly increasing the frequency of transgenic cells (Figure 3a) but not to increase transgene expression in primary hematopoietic cells. We suggest testing WPRE not only in combination with the cDNA 19 being employed, but also with the promoter and, most importantly, with the target cell type. A moderate reduction of expression may often be tolerated in favor of a significantly higher vector titer.
Successful cell-specific transgene expression in hematopoietic cells has been achieved for erythroid cells 44 and major histocompatibility complex class II þ cells. 45 Recently, also CD4 þ cells were transcriptionally targeted with lentiviral vectors employing the regulatory sequence of the CD4 gene, 46 respectively. We have shown that a fragment of 999 bp of the human CD19 promoter is sufficient to direct transgene expression specifically to B cells throughout their development in primary and secondary lymphoid organs. Interestingly, increasing the frequency of transduced B cells in vivo by multiple transductions was associated with an increase in nonspecific transgene expression (Figure 5b ). This is likely related to an increased risk of insertions in the vicinity of active cellular enhancers when transducing multiple copies per cell. In transgenic mice, nonspecific expression of the transgene from the 4.2 kb promoter region of the human CD19 gene as a result of high copy numbers has been observed (unpublished observations). Therefore, with the system presented here, B-cell-specific transgene expression goes along with a moderate frequency of transgenic cells. Using a lentiviral vector with ubiquitous viral or cellular promoters in combination with B-cell-specific enhancer and matrix attachment regions, Lutzko et al 47 could increase transgene expression specifically and position-independent in B cells. Conceivably, the matrix attachment regions and the B-cell-specific enhancer described by this group might be effective in protecting the human CD19 promoter against the influence of the chromosomal environment and increasing its relatively weak transgene expression.
The promoter region of the human and the murine CD19 gene is not sequence-identical, 30 and studies in transgenic mice 26 coexpressing both showed differential regulation of gene expression. Expression of the human CD19 gene in transgenic mice increased with B-cell maturation and correlated with changes observed during human B-cell development, whereas expression of murine CD19 was detected on most B cells with expression upregulated at specific times during B-cell development. In contrast, we observed uniform expression of the transgene in all developmental stages in different organs; no upregulation of gene expression was detected at any stage of B-cell differentiation. Additional control elements located in the promoter region as well as in the human CD19 coding-sequence itself are probably required for gene expression resembling transcriptional control of the human CD19 locus. These may be of interest for fine-tuning of retroviral B-cellspecific transgene expression. Importantly, the vector conferred long-term expression in a significant proportion of B cells without any selection pressure. Although we observed a decreased frequency of eGFP-expressing B cells in 75% of the mice almost 1 year after bone marrow transplantation, the decrease was not, in most cases, too pronounced. None of the mice had complete extinction of transgene expression, which has been observed by others using different vectors. 48, 49 B-cell specificity, along with the potential for long-term expression, render the pSIN-CD19-W vector a promising candidate for correction of B-cell deficiencies, hopefully increasing both efficiency and safety of the gene therapeutic intervention. In addition, this vector opens opportunities for development of immunotherapies or models of B-cell malignancies and studies of the impact of various molecules specifically on B cells, advancing our understanding about their roles in B-cell development as well as B-cell function and regulation.
Materials and methods
Cell lines
Phoenix eco (ecotropic retroviral packaging cell line, http://www.stanford.edu/group/nolan) and NIH3T3 (murine fetal fibroblasts) cells were cultured in high glucose Dulbecco's modified Eagle's medium with glutamax, 10% fetal bovine serum and penicillinstreptomycin (Gibco BRL, Invitrogen Corporation, Carlsbad, CA, USA). All cells were kept at 371C in a humidified atmosphere in CO 2 incubators (Heraeus, Hannover, Germany) with the exception of virus generation, which was performed at 321C.
Retroviral vectors
The SIN vectors used here are based on pSF110, 19 carrying eGFP as marker. The enhancer-promoter was B-cell-specific SIN vector M Werner et al deleted from the 3 0 LTR using a PCR-based strategy, leaving only the first 22 bp and last 14 bp of the U3 region. The SFFV enhancer-promoter isolated from pSF110 as an NheI-KpnI fragment was introduced 3 0 of the packaging signal. The resulting vector was named pSIN-SF (JK and CB, unpublished data). The WPRE sequence was isolated from pSFb91-eGFP-WPRE 19 as an EcoRI fragment and cloned into pSIN-SF, generating pSIN-SF-eGFP-WPRE (SIN-SF-W). The SIN-vector carrying the human CD19 promoter in combination with WPRE sequence (SIN-CD19-W) is based on SIN-SFFV-W. A 999 bp fragment (À1018 bp to À19 bp) of the human CD19 promoter was amplified by PCR from a plasmid carrying 4.2 kb of the 5 0 untranslated region of the human CD19 gene 28 using Pwo polymerase (ThermoHybaid, Ashford, Middlesex, UK) and the following primers: 5 0 -ATCTATAGCGGCCGCTTTTCTGAGTCCC TGCAGCAGTG-3 (5 0 primer, containing a NotI site) and 5 0 -ATAACCGGTCGCGAGCACCCAGCTTCGCG CA-3 0 (3 0 primer containing a NruI and a AgeI site). The amplified sequence was cloned as a NotI-AgeI fragment into SIN-SF-W, replacing the SFFV enhancerpromoter. To construct SIN-CD19, the hCD19 promoter in combination with eGFP was cloned as a NotI-HindIII fragment into SIN-SF.
Vector production
Phoenix eco cells were transfected using standard calcium phosphate transfection. Briefly, 7.5 Â 10 6 cells were transfected with 60 mg of vector-DNA. Supernatants were routinely generated 24-48 h post-transfection by overnight incubation in Phoenix growth medium at 321C. Vector stocks were filtered (0.45 mm filter, Nalgene, Rochester, NY, USA) and immediately used or snap-frozen and stored at À801C for later use. Viral titers were determined by spin-infection (300 g, 2 h, 30-321C) of 8 Â 10 4 NIH3T3 cells with 1 ml of serial dilutions of virus-containing supernatant in the presence of polybrene (8 mg/ml, Sigma, St Louis, MO, USA), followed by flow cytometric analysis or quantitative real-time PCR. Titers were calculated as transducing units/ml (TU/ml): % eGFP þ cells Â dilution Â cell number at time of infection.
Quantitative real-time PCR
Genomic DNA was purified by using the DNeasy Tissue Kit (Quiagen, Hilden, Germany). Quantitative real-time PCR was performed using the LightCycler system (Roche Diagnostics, Penzberg, Germany). In brief, primers gfp-f 5 0 -TATATCATGGCCGACAAGCA-3 0 and gfp-r 5 0 -ACTGGGTGCTCAGGTAGTG-3 0 amplified a 162-bp fragment from the eGFP cDNA. Primers bdnf-f 5 0 -ACGACATCACTGGCTGACAC-3 0 and bdnf-r 5 0 -CAT AGACATGTTTGCGGCATC-3 0 amplified a 206-bp fragment from the brain-derived neurotrophic factor (BDNF) gene, a single-copy-number housekeeping gene. 50 All primers were obtained from MWG Biotech (Ebersberg, Germany). Duplicate samples of 1 ml each were amplified in the presence of 8 mM primer pairs, 3 mM MgCl 2 , 1 Â LC TM -FastStart DNA Master SYBR Green I. Each sample was measured in duplicates and analyzed three times by quantitative real-time PCR. The PCR cycling conditions were set as follows: an initial denaturing step at 951C for 10 min and 40 cycles at 951C for 10 s, 601C for 5 s, and 721C for 10 s. For each of the two reactions, the PCR cycle number that generated the first fluorescence signal above a threshold was determined (the crossing point CP). The difference between the CP of reaction 1 and 2 (Delta CP) was used to quantify the percentage of vector transduced target cells with the help of a standard curve. The standard curve was obtained with 10-fold serial dilutions of genomic DNA from a murine B-cell line (mb-1 MCM:mEGFP, kindly provided by Elias Hobeika, Freiburg, Germany) with only one eGFP-copy per cell.
In vivo studies
C57Bl/6 mice were bred in the animal facility of the Institute for Immunology (Munich, Germany). Bone marrow cells were harvested 4 days after intravenous injection of 5-FU (150 mg/kg body weight, Amersham Pharmacia, Uppsala, Sweden) from femurs and tibiae of female donor mice (age: 8-10 weeks) and prestimulated for 2 days in IMDM supplemented with 20% fetal bovine serum, penicillin-streptomycin (Gibco BRL, Invitrogen Corporation, Carlsbad, CA, USA) and a growth factor cocktail containing hIL-6 (200 U/ml), mIL-3 (10 ng/ml) and murine SCF (50 ng/ml). Recombinant growth factors were purchased from Strathmann Biotech (Hannover, Germany). After prestimulation, cells were transduced by spin-infection (300 g, 2 h, 30-321C) with cell-free supernatants of ecotropic retroviral particles in the presence of polybrene (4 mg/ml). Alternatively, this transduction procedure was repeated one or two times in intervals of at least 14 h between individual infections. One day after the final transduction, 3 Â 10 6 cells/mouse were injected intravenously into lethally irradiated (split dose day -2 and day 0: 550 rad) female C57Bl/6 recipients (age 10-15 weeks).
Monoclonal antibodies and reagents
The monoclonal antibodies specific for CD4 (clone H129.19), CD8 alpha chain (clone 53-6.7), CD11b alpha chain (clone M1/70), CD19 (clone 1D3) and Ly6G/Ly6C as well as streptavidin reagents were purchased from Becton Dickinson/Pharmingen (Mountain View, CA, USA). Flow cytometry was performed on a FACScalibur (Becton Dickinson, Mountain View, CA, USA) instrument and analyzed with CellQuest.
Analysis of transgene expression
Expression of eGFP in retrovirally transduced NIH3T3 cells and cells from peripheral blood, spleen and bone marrow was measured by flow cytometry. Mononuclear cells from peripheral blood were obtained by Ficoll density-gradient separation. Single-cell preparations, stainings and flow cytometric analysis were performed according to standard procedures.
